Antibody-based drug discovery at the speed of light
webinar
internal
The combination of the PentaMice® platform and single B cell screening with the Berkeley Lights Beacon® Optofluidic system increases speed to market for monoclonal antibody therapeutics.
The Beacon® system is an innovative package using the technology of light, nanofluidics and refined AI algorithms to identify and orchestrate the movement of single B cells into a grid of NanoPen™ chambers for screening.
Download our white paper for insights on:
- First-to-Human antibody therapeutics
- Immunization — PentaMice® platform for antibody generation
- Single B cell screening with the Beacon® system
- Sequence Identification
- Custom Bioinformatics
- Case Study: Discovery of diverse monoclonal antibodies that bind SARS-CoV-2 Delta and Omicron spike proteins
Gene-to-Protein Strategies